Fortrea and Omico partner to match Australian cancer patients with clinical trials
Global contract research organization Fortrea and Australian screening network Omico have partnered to help connect cancer patients to targeted biomarker clinical trials.
FTMQ Health, written by our newsroom0 views
Contract research organization Fortrea and Australian trial matching network Omico announced a collaboration on October 22, 2026, AAP reported. The partnership aims to accelerate precision oncology research by helping connect cancer patients with biomarker-matched clinical trials in Australia. [1][2]
The collaboration is designed to improve clinical trial planning and expand patient access to targeted cancer studies. Stock Titan reported that Omico maintains databases containing more than 23,000 consented cancer patients, which Fortrea aims to leverage to link individuals directly to research trials. [1][3]
Fortrea is an American contract research organization headquartered in Durham, North Carolina, operating across roughly 100 countries. It provides research services primarily to the biotechnology, medical device, and pharmaceutical industries. [1][5]
Omico serves as Australia's primary precision oncology screening and trial matching organization. The joint effort seeks to advance biomarker-led oncology drug development across the region by expanding trial access for eligible patients. [1]
In short
- Fortrea and Omico announced a collaboration on October 22, 2026, to advance precision oncology research.
- Omico holds databases with over 23,000 consented cancer patients.
- The partnership aims to expand Australian patient access to biomarker-matched clinical trials.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Developmentaapnews.aap.com.au, 4h ago (the report this story comes from)
- [2]Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug DevelopmentGlobeNewswire, 4h ago
- [3]Over 23,000 consented patients are in Omico's cancer databases; Fortrea aims to link patients to trials.Stock Titan, 4h ago
Background
- [4]Merck & Co. on Wikipedia
- [5]Fortrea on Wikipedia
Our newsroom writes these reports with the help of software, from the 5 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- Targeted screening in Malawi could improve tuberculosis detection and lower costsMedical Science, 15d ago
More in Medical Science
- Researchers publish framework to improve outcome definitions in clinical trials1d ago
- Breast cancer trial in Australia and New Zealand tests chemotherapy avoidance1d ago
- New brain injury framework evaluated in large human observational studies2d ago
- Ohio State trial examines whether probiotics reduce ovarian cancer treatment side effects2d ago
- Chinese study shows clinical research training boosts medical undergraduate interest2d ago
- University of Oklahoma receives funding to study combined myeloma treatment3d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.
Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.